A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
详细信息 查看全文
- 作者：John Y. Li1 ; lij@medimmune.com" class="auth_mail" title="E-mail the corresponding author ; Samuel R. Perry1 ; Vanessa Muniz-Medina1 ; Xinzhong Wang1 ; 6 ; Leslie K. Wetzel2 ; Marlon C. Rebelatto3 ; Mary Jane Masson Hinrichs3 ; Binyam Z. Bezabeh4 ; Ryan L. Fleming4 ; Nazzareno Dimasi4 ; Hui Feng4 ; 7 ; Dorin Toader4 ; Andy Q. Yuan4 ; Lan Xu4 ; Jia Lin4 ; Changshou Gao4 ; Herren Wu4 ; Rakesh Dixit3 ; Jane K. Osbourn1 ; 5 ; Steven R. Coats1
- 刊名：Cancer Cell
- 出版年：2016
- 出版时间：11 January 2016
- 年：2016
- 卷：29
- 期：1
- 页码：117-129
- 全文大小：3475 K
文摘
- •
Dual targeting of HER2 by biparatopic ADC enhances toxin delivery into tumor cells
- •
HER2 biparatopic ADC induces greater breadth of tumor cell killing than T-DM1
- •
HER2 biparatopic ADC kills tumor cells relapsed/refractory to T-DM1 treatment